Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Ovarian Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Endometrial Neoplasms 2mCRPC 1Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Hemangiosarcoma 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1

Interventions

X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2LY3023414 2talazoparib 1olaparib 1irinotecan sucrosofate 1amino-acid, glucose, and electrolyte solution 1Vemurafenib 1Temozolomide 1Pharmacogenomic Variants 1Liquid Biopsy 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive, Peripheral × talazoparib × 90 days × Clear all
NCT04901702 2026-05-19

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
90 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡